Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 214

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 214
---
-pocketexpenses, including legal fees and expenses, incurred by Wainwright in connection with financial advisory agreement. Dr. Kira Sheinerman, the co -founderof DiamiR, is currently a managing director of Wainwright. 112 INFORMATION ABOUT APTORUM We are a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company now focuses all of its efforts on R&D and therefore no longer performs any therapeutic services. While the Company may commence therapeutic services in the future, as of December 31, 2024 and the date hereof, it only operates in one segment. Our goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this goal include: (for details of our strategy, See “Business Overview — Our Strategy”) •Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; •Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; •Collaborating with leading academic institutions and CROs; •Expanding our in -housepharmaceutical development center; •Leveraging our management’s expertise, experience and commercial networks; •Obtaining and leveraging government grants to fund project development. We have devoted a substantial portion of the proceeds from our offerings, to our Lead Projects. Our Lead Projects are ALS -4and SACT -1. In March 2023, we announced that we completed the Pre -INDdiscussions with the US FDA on ALS -4. In March 2023, we also announced the completion of the End of Phase 1 (EOP1) meeting of SACT -1with the US FDA. The FDA generally agreed with the chemistry -manufacturing -control(CMC) strategy and our proposed clinical development plan for SACT -1Phase 1/2 trials. Currently, ALS -4and SACT -1are Phase 2 clinical trials ready. During the second quarter of 2023, the Company made a decision to streamline its operations by terminating clinic services and suspending non -leadR&D projects. This measure is aimed at optimizing the allocation of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for